Strategic Acquisition NeuroMetrix is now a wholly owned subsidiary of electroCore, creating a potential sales channel and cross-sell opportunities for electroCore’s portfolio while maintaining NeuroMetrix’s established Quell brand and product lines.

Product Expansion Recent launches including DPNCheck 2.0 and SENSUS Pain Management System, plus a Quell Fibromyalgia device, indicate ongoing product modernization and new end-user applications that can be marketed to clinicians, pain specialists, and chronic pain patients.

Clinical Focus A strong emphasis on non-invasive diagnostic and therapeutic devices for peripheral neuropathy and chronic pain positions the company to target neurology, pain management clinics, and primary care networks seeking at‑the‑point‑of‑care solutions.

Market Readiness With a mid‑sized, specialized footprint and revenue in the low single digits, NeuroMetrix presents a lean, potentially faster sales cycle for pilots or Pathfinder programs, leveraging established DPNCheck and Quell platforms.

Strategic Partnerships The combination of Harvard‑MIT origin, clinical heritage, and integration under electroCore opens opportunities for co‑marketing with academic centers, contract research, and expanded reimbursement discussions to accelerate adoption.